Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AstraZeneca PLC ADR (AZN) is a leading drug manufacturers-general business based in the US. It opened the day at $64.15 after a previous close of $66.07. During the day the price has varied from a low of $64.07 to a high of $65.97. The latest price was $65.95 (25 minute delay). AstraZeneca PLC ADR is listed on the NASDAQ and employs 83,100 staff. All prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Since the stock market crash in March caused by coronavirus, AstraZeneca PLC ADR's share price has had significant positive movement.
Its last close price was $65.95, which is 23.93% up on its pre-crash value of $50.17 and 82.43% up on the lowest point reached during the March crash when the shares fell as low as $36.15.
If you had bought $1,000 worth of AstraZeneca PLC ADR shares at the start of February 2020, those shares would have been worth $799.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1.00.
In mid-November 2021, AstraZeneca announced that its COVID-19 vaccine, which was developed in partnership with the University of Oxford, has an average efficacy of 70%. In some clinical tests, the vaccine was 90% effective. The company says it shipped over 2 billion doses of the vaccine available as of December, 2021.
The company’s vaccine follows news that Moderna and Pfizer have each developed vaccines. Shares of AstraZeneca (AZN) were down following the news.
| Open | $64.15 |
|---|---|
| High | $65.97 |
| Low | $64.07 |
| Close | $65.95 |
| Previous close | $66.07 |
| Change | $-0.12 |
| Change % | -0.1816% |
| Volume | 8,850,093 |
| 52-week range | $52.76 - $71.70 |
|---|---|
| 50-day moving average | $64.77 |
| 200-day moving average | $61.30 |
| Wall St. target price | $71.80 |
| PE ratio | N/A |
| Dividend yield | $2.87 (2.17%) |
| Earnings per share (TTM) | $-0.36 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $65.95 from 2022-07-01
| 1 week (2022-06-27) | -0.84% |
|---|---|
| 1 month (2022-06-03) | 0.38% |
| 3 months (2022-04-04) | -1.08% |
| 6 months (2022-01-04) | 15.16% |
| 1 year (2021-07-02) | 8.49% |
|---|---|
| 2 years (2020-07-02) | 22.58% |
| 3 years (2019-07-03) | 57.06% |
| 5 years (2017-07-03) | 94.66% |
Valuing AstraZeneca PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AstraZeneca PLC ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4649. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca PLC ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AstraZeneca PLC ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.7 billion.
The EBITDA is a measure of a AstraZeneca PLC ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $41.5 billion |
|---|---|
| Operating margin TTM | 15.15% |
| Gross profit TTM | $27.6 billion |
| Return on assets TTM | 4.76% |
| Return on equity TTM | -4.17% |
| Profit margin | -2.56% |
| Book value | $11.74 |
| Market capitalisation | $204.4 billion |
TTM: trailing 12 months
Dividend payout ratio: 51.62% of net profits
Recently AstraZeneca PLC ADR has paid out, on average, around 51.62% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.17% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca PLC ADR shareholders could enjoy a 2.17% return on their shares, in the form of dividend payments. In AstraZeneca PLC ADR's case, that would currently equate to about $2.87 per share.
AstraZeneca PLC ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AstraZeneca PLC ADR's most recent dividend payout was on 27 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 23 February 2022 (the "ex-dividend date").
AstraZeneca PLC ADR's shares were split on a 2:1 basis on 26 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca PLC ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca PLC ADR shares which in turn could have impacted AstraZeneca PLC ADR's share price.
Over the last 12 months, AstraZeneca PLC ADR's shares have ranged in value from as little as $52.7574 up to $71.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca PLC ADR's is 0.1224. This would suggest that AstraZeneca PLC ADR's shares are less volatile than average (for this exchange).
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
